Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Monday, April 22, 2024 | Back issues
Courthouse News Service Courthouse News Service

Amylin Pharmaceuticals

The board of directors for Amylin Pharmaceuticals refuse to defuse proxy puts that would force the company to repay $900 million in outstanding debt if a majority of its 12 directors are replaced in a proxy contest, a shareholder class action claims in Delaware Chancery Court.

Directors could neutralize the situation by approving two election slates, but they refuse to do so because they want to remain in office, the lawsuit claims.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.